Recommended Topic Related To:

DDAVP Injection

"A drug candidate developed by researchers at the NIH's National Center for Advancing Translational Sciences (NCATS) and its collaborators to treat sickle cell disease has been acquired by Baxter International's BioScience business. The drug c"...

DDAVP Injection

OVERDOSE

Signs of overdose may include confusion, drowsiness, continuing headache, problems with passing urine and rapid weight gain due to fluid retention. (See WARNINGS.) In case of overdosage, the dosage should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition.

There is no known specific antidote for desmopressin acetate or DDAVP Injection (desmopressin acetate injection) 4 mcg/mL.

An oral LD50 has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.

CONTRAINDICATIONS

DDAVP Injection (desmopressin acetate injection) 4 mcg/mL is contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of DDAVP Injection 4 mcg/mL.

DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

DDAVP is contraindicated in patients with hyponatremia or a history of hyponatremia.

Last reviewed on RxList: 2/12/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

DDAVP Injection - User Reviews

DDAVP Injection User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication DDAVP Injection sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.